Clinical trials: Biliary Tract Adenocarcinoma
Biliary Tract Cancer, Cholangiocarcinoma
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- CHOCA (NCT05184400)
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- Herlev and Gentofte Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Biliary Tract Cancer, Cholangiocarcinoma
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in…
- Trial name
- PURITY (NCT06037980)
- Testing
- Gemcitabine, Nab paclitaxel, Cisplatin
- Where
- 19 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Malignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
The present study is designed to determine whether adjuvant concurrent chemoradiotherapy improves overall survivals.
- Trial name
- NCT02798510
- Testing
- Concurrent Chemoradiotherapy, capecitabine, gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Biliary Tract Neoplasm, Cholangiocarcinoma
MRCP Diagnoses EHCC Better When Combined DWI
Researching the diagnostic significance of Biliary Tract Neoplasm under combining DWI sequence with MRCP versus MRCP only separately.
- Trial name
- NCT01595217
- Testing
- 3T MRI
- Where
- China
- Volunteers
- 99 people
- Sponsor
- China Medical University, China
Biliary Tract Cancer
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
The purpose of this research study is to determine the safety and efficacy of CPI-613 (devimistat) in the treatment of advanced biliary tract cancer when used in combination with standard of care chemotherapy (gemcitabine plus…
- Trial name
- NCT04203160
- Testing
- CPI 613, Gemcitabine, Cisplatin
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations.
- Conditions
- Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
- Trial name
- NCT04042831
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Academic and Community Cancer Research United
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
HER2-positive Breast Cancer, Cervical Cancer
Tucatinib Continuation Study
The purpose of this protocol is to give continued access to tucatinib eligible participants. It also enables ongoing safety follow-up for those who continue to benefit from the study treatment.
- Conditions
- HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer
- Trial name
- NCT07768358
- Testing
- tucatinib
- Volunteers
- 175 people
- Sponsor
- Pfizer
Obstruction of Biliary Tree, Cholangiocarcinoma
Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent
Internal biliary drainage is an useful method for a control of jaundice and cholangitis to patients who had a malignant hilar obstruction due to hepatocellular carcinoma, cholangiocarcinoma, gall bladder cancer or metastatic…
- Conditions
- Obstruction of Biliary Tree, Cholangiocarcinoma, Hepatocellular Carcinoma, Malignant Lymphadenopathy
- Trial name
- NCT01875549
- Testing
- stent insertion, Endoscopic retrograde cholangiopancreatoscopy(ERCP)
- Sponsor
- Kwang Hyuck Lee
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Carcinoma
Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma
This is a multi-centre phase II, open-label, randomized (1:1), parallel-arm, study of panitumumab in combination with chemotherapy (P-GEMOX) versus chemotherapy alone (GEMOX).
- Trial name
- Vecti-BIL (NCT01389414)
- Testing
- Panitumumab plus GEMOX chemotherapy, GEMOX chemotherapy
- Where
- 12 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Prof. Massimo Aglietta
Advanced Biliary Tract Adenocarcinoma
Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma
The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma
- Trial name
- NCT01082809
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Samsung Medical Center
Biliary Tract Cancer, Cholangiocarcinoma
SHR-1210 in Combination With GEMOX in Patients With Advanced BTC
This is a single-arm, open-label and exploratory clinical study of PD-1 monoclonal antibody SHR-1210 combined with GEMOX regimen (gemcitabine combined oxaliplatin) in the treatment of advanced biliary malignancies.
- Trial name
- NCT03486678
- Testing
- SHR-1210+GEMOX
- Where
- China
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholecystitis, Hepatocellular Carcinoma
Low Dose ICG for Biliary Tract and Tumor Imaging
Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy.
- Conditions
- Cholecystitis, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- ICG (NCT04942665)
- Testing
- Indocyanine green, PINPOINT Endoscopic Fluorescence
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Hepatocellular Carcinoma, Bile Duct Cancer
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
The purpose of this study is to explore the ability of positron emission tomography (PET) with [68Ga]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with…
- Trial name
- NCT05662488
- Testing
- [68Ga]FAPI PET/CT and [18F]FDG PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking Union Medical College Hospital
Cholangiocarcinoma, Gallbladder Cancer
Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
To determine the activity of gemcitabine combined with carboplatin in the treatment of patients with metastatic or recurrent cholangiocarcinoma or gallbladder cancer.
- Trial name
- NCT00660140
- Testing
- Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Washington University School of Medicine
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well trastuzumab works in treating patients with locally advanced or metastatic gallbladder cancer or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Malignant Neoplasm, Recurrent Extrahepatic Bile Duct Cancer
- Trial name
- NCT00478140
- Testing
- trastuzumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)